ABSTRACT
Recent studies have found that prostate cancer expresses abnormal genetic markers including multiple types of TMPRSS2-ERG fusion genes. The expression level of different TMPRSS2-ERG fusion genes is correlated to pathologic variables of aggressive prostate cancer and disease progression. State-of-the-art methods for detection of TMPRSS2-ERG fusion genes include reverse transcription polymerase chain reaction (RT-PCR) with a detection limit of 1 fmol at urinary condition. RT-PCR is time consuming, costly, and inapplicable for multiplexing. Ability to identify multiple fusion genes in a single sample has become important for diagnostic and clinical purposes. There is a need for a sensitive diagnostic test to detect multiple TMPRSS2-ERG fusion genes for an early diagnosis and prognosis of prostate cancer. Here, we propose to develop an assay for prostate cancer diagnosis using oligonucleotide-functionalized quantum dot and magnetic microparticle for optical detection of rearranged TMPRSS2-ERG fusion genes at a low concentration in urine. We found that our assay was able to identify three different types of fusion gene with a wide detection range and detection limit of 1 fmol (almost the same level of the RT-PCR result reported). Here, we show detection of multiple TMPRSS2-ERG fusion genes using color-coded oligonucleotides in cell lysate and urine.
Subject(s)
Oncogene Proteins, Fusion/urine , Optics and Photonics/methods , Prostatic Neoplasms/genetics , Quantum Dots , Cell Line, Tumor , Humans , Magnetite Nanoparticles , Male , Oncogene Proteins, Fusion/analysis , Oncogene Proteins, Fusion/genetics , Optics and Photonics/instrumentation , Prognosis , Prostatic Neoplasms/urine , Quantum Dots/chemistryABSTRACT
Identifying genetic diversity is important for studies in cancer as it can provide insights on disease progression and treatment. Although clinical outcome and major symptom of cancer might be same in all patients, the type of overexpressed gene could be different. Even though prostate-specific antigen assay is a good tool widely used for prostate cancer diagnosis, it is not capable of providing information on genetic differences. Therefore, screening method that can differentiate genetic differences is necessary. Here we detected different types of TMPRSS2-ERG, prostate cancer specific fusion genes, to verify the genetic diversity between the patients using high throughput screening method, bio-barcode assay. Prostate cancer patients with different types of fusion gene were successfully differentiated directly from untreated patients' urine, while traditional PSA assay could not. This non-invasive assay, when used with PSA assay, can be a strong secondary screening method which can offer new insights on disease progression and clinical outcome.
Subject(s)
Biomarkers, Tumor/urine , Oncogene Proteins, Fusion/urine , Prostatic Neoplasms/urine , Serine Endopeptidases/metabolism , Transcriptional Regulator ERG/metabolism , Biological Assay/methods , Humans , Male , Prostate/metabolism , Prostate-Specific Antigen/metabolism , Serine Endopeptidases/genetics , Transcriptional Regulator ERG/geneticsABSTRACT
The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.
Subject(s)
Drug Delivery Systems , Nanomedicine , Animals , Antineoplastic Agents/administration & dosage , Drug Approval , Drug Design , Humans , Immunoconjugates/administration & dosage , Nanoparticles/administration & dosage , Neoplasms/drug therapy , Neoplasms/metabolism , United States , United States Food and Drug AdministrationABSTRACT
The water solubilization of nanoparticles is key for many applications in biomedicine. Despite the importance of surface functionalization, progress has been largely empirical and very few systematic studies have been performed. Here we report on the water solubilization of quantum dots using lipid encapsulation. We systematically evaluate the monodispersity, zeta potential, stability, and quantum yield for quantum dots encapsulated with single and double acyl-chain lipids, pegylated double acyl-chain lipids, and single alkyl-chain surfactant molecules with charged head groups. We show that charged surfactants and pegylated lipids are important to obtain monodisperse suspensions with high yield and excellent long-term stability. FROM THE CLINICAL EDITOR: This study reports on solubilization of nanoparticles in water, a key, but often neglected aspect for biomedical applications. The authors demonstrate that charged surfactants and PEGylated lipids are important to obtain monodisperse suspensions with high yield and long-term stability.